BioCryst Pharmaceuticals | BCRX - Gross Profit On Sales


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview

BioCryst Pharmaceuticals

BioCryst Pharmaceuticals reported $67.84M in Gross Profit on Sales for its fiscal quarter ending in March of 2023.


Gross Profit On Sales Change
Alnylam Pharmaceuticals ALNY:US USD 264.42M 19.35M
BioCryst Pharmaceuticals BCRX:US USD 67.84M 9.21M
Chugai Pharma 4519:JP JPY 160.91B 64.68B
Daiichi Sankyo 4568:JP JPY 224.22B 18.28B
Gilead Sciences GILD:US USD 4.95B 1.04B
GlaxoSmithKline GSK:LN GBP 5.05B 151M
Glaxosmithkline GSK:US GBP 5.05B 151M
Incyte Corp INCY:US USD 757.25M 115.69M
Intra Cellular Therapies ITCI:US USD 88.56M 7.47M
Ionis Pharmaceuticals IONS:US USD 129.18M 19.02M
Karyopharm Therapeutics KPTI:US USD 37.35M 5.64M
Mirati Therapeutics MRTX:US USD 6.35M 6.02M
Neurocrine Biosciences NBIX:US USD 411.9M 7.6M
Novavax NVAX:US USD 46.86M 128.77M
PTC Therapeutics PTCT:US USD 206.24M 49.72M
Regeneron Pharmaceuticals REGN:US USD 2.7B 169.2M
Roche Holding ROG:VX CHF 22.04B 696M
Sarepta Therapeutics SRPT:US USD 218.48M 9.14M
Ultragenyx Pharmaceutical RARE:US USD 88.24M 9.79M
Vertex Pharmaceuticals VRTX:US USD 2.11B 88.5M